Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Hematology
Disease Category: Aplastic Anemia

Trial Information

BMT CTN 0301: Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia

You have/your child has been asked to participate in this research study because you have/your child has Severe Aplastic Anemia (SAA).  An allogeneic (from a donor) bone marrow transplant can be used to treat SAA.  You do/your child does not have a matched related donor and will need to receive cells from a matched, unrelated donor (not a blood relative).  The purpose of this study is to see how much the dose of cyclophosphamide (a medication used to reduce the number of diseased cells and lower the immune system to the body to accept donor marrow cells) can be lowered when fludarabine is added to the pre-transplant medications in order to lower the side effects while still allowing the donor marrow cells to replace the diseased marrow cells.  Your/your child’s participation in this study is expected to last approximately 3 to 6 months for transplant treatment and indefinitely for follow-up.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.